grant

Regulation of re-replication in mammalian cells

Organization UNIVERSITY OF VIRGINIALocation CHARLOTTESVILLE, UNITED STATESPosted 1 Mar 2020Deadline 31 Dec 2026
NIHUS FederalResearch GrantFY2024AffectBio-InformaticsBioinformaticsCancersCell BodyCell CycleCell Division CycleCell LineCellLineCellsCharacteristicsChromatinChromosomesComplementComplement ProteinsComplexDNA Damage RepairDNA Double Strand BreakDNA RepairDNA Repair GeneDNA ReplicationDNA Replication InductionDNA Replication InitiationDNA SynthesisDNA biosynthesisDNA dependent protein kinase catalytic subunitDNA repair proteinDNA replication originDNA-PKcsDevelopmentDouble Strand Break RepairEC 2.1.1Enzyme GeneEnzymesEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEukaryotaEukaryoteExhibitsFISH TechnicFISH TechniqueFISH analysisFISH assayFailureFire - disastersFiresFirst Gap PhaseFluorescence In Situ HybridizationFluorescent in Situ HybridizationG1 PhaseG1 periodGap Phase 1Gene Down-RegulationGene InactivationGene SilencingGenerationsGenesGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyGenomeGenome InstabilityGenomic InstabilityGenomic SegmentGenomicsGoalsHistonesL3MBTL1L3MBTL1 geneLicensingM PhaseMalignantMalignant - descriptorMalignant CellMalignant NeoplasmsMalignant TumorMammalian CellMediatingMethylationMethyltransferaseMitosisMitosis StageModelingMolecularNatureNuclearPopulationProcessProteinsReaderRecombinant DNA TechnologyRegulationReplication InitiationReplication LicensingReplication OriginResistanceRoleS PeriodS phaseSiteSortingStochastic ProcessesStrains Cell LinesSynthesis PeriodSynthesis PhaseTestingTranscription RegulationTranscription RepressionTranscription RepressorTranscriptional ControlTranscriptional RegulationTranscriptional RepressionTranscriptional RepressorTransferaseTransferase GeneUnscheduled DNA Synthesisanti-cancer therapeuticcancer cellcell typecomplementationcultured cell linecytotoxicdesigndesigningdevelopmentalentire genomeepigenetic regulationepigeneticallyfirefull genomegene locusgene repressiongenetic locusgenetic repressorgenetically engineeredgenome segmentgenome sequencinggenomic locationgenomic locusgenomic regionhistone H3 methyltransferasehistone methylasehistone methyltransferaseimprovedinnovateinnovationinnovativemalignancymethylasemutantneoplasm/cancernovelori Regionpharmacologicrecruitresistantsocial rolestochastic methodtranscriptional silencingtransmethylasewhole genome
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Project Summary
Mammalian cells have evolved multiple non-overlapping mechanisms to ensure that DNA replication initiates

from origins of replications once and only once in each division cycle; loss of control over these mechanisms

induces genomic instability, an important driver of malignant transformation. Increasing evidence suggests that

origin utilization and activation in higher eukaryotes is influenced by epigenetic factors, but exact mechanisms

are largely undefined. Our long-term goals are to elucidate the underpinning mechanisms that control replication

initiation in mammalian cells and to understand how perturbations of these mechanisms provokes genomic

instability. The histone methyltransferase SET8 is emerging as a key regulator of replication initiation in

mammalian cells through its mono-methyltransferase activity on histone H4K20. The cell cycle regulated enzyme

is essential for origin licensing in G1 phase of the cell cycle, but is proteolytically degraded in S-phase; blocking

this step triggers reiterative replication initiation within the same cell cycle or re-replication. Both SET8 and

H4K20me, however, are also involved in transcriptional repression and in the repair of DNA double strand breaks

(DSBs), but whether these seemingly independent activities play a role in replication initiation or re-replication is

not known. Most importantly, little to nothing is known about the nature or characteristics of the re-replication

products that accumulate in cells with defective SET8 degradation, nor is there information on where in the

genome re-replication occurs or if certain genomic regions are more prone to re-replication induction. Our new

results show that re-replication resulting from defective SET8 degradation is not a stochastic process, with few

genomic sites exhibit large and significant copy number gains, reminiscent of genomic amplifications that are

seen in cancer cells. Additional preliminary studies suggest that re-replication may originate from DNA double

strand breaks (DSBs) that may spontaneously arise during replication, and requires the activity of genes involved

both in transcriptional silencing and in DSB repair. Our innovative preliminary studies and experimental

approaches are designed to thoroughly examine this alternative model of re-replication induction. In Aim 1, we

will determine the magnitude (copy number gains) and genomic distribution of the re-replicated DNA in bulk and

single cells with defective SET8 degradation and following the induction of DSBs at defined genomic sites. We

will also test if these parameters vary in different cancer cell types and in cancer vs. non-cancer cells. In Aim 2,

we will define the roles of histone H4K20 methylation, transcriptional silencing by the H4K20me reader

L3MBTL1, and proteins involved in the repair of DSBs in effecting re-replication. The successful execution of the

proposed aims promises to increase our understanding of the mechanisms regulating replication initiation in

mammalian cells, and lead to a better understanding of how perturbations of these mechanisms provokes

genomic instability.

Grant Number: 5R01GM135376-05
NIH Institute/Center: NIH

Principal Investigator: TAREK ABBAS

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →